|Bid||3.2600 x 4000|
|Ask||3.2900 x 4000|
|Day's Range||3.2200 - 3.3000|
|52 Week Range||1.4500 - 5.5000|
|Beta (5Y Monthly)||1.47|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Shareholders in Rigel Pharmaceuticals, Inc. ( NASDAQ:RIGL ) may be thrilled to learn that the analysts have just...
Rigel (RIGL) delivered earnings and revenue surprises of -10.00% and 0.44%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Rigel Pharmaceuticals (NASDAQ: RIGL) recently popped after the company announced a collaboration deal with one of America's largest drugmakers, Eli Lilly (NYSE: LLY). A new collaboration deal with a big pharmaceutical company isn't the only reason to keep an eye on this often overlooked biotech stock. Here's why investors can look forward to outstanding returns from Rigel Pharmaceuticals in the years to come.